2026
- Humar A, Hadjiyannis Y, Macedo C, Tran LM, Elinoff BD, Hughes CB, Ganesh SR, Zahorchak AF, Ables EM, Styn MA, Landsittel D, Zeevi A, Lakkis FG, Metes DM, Thomson AW. Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial. Nature Communications. (2026)April:17:3226 https://www.nature.com/articles/s41467-026-71280-8
- Kirtane K, Kalos M, Billups R, Chapuis AG, Coutinho V, Feldman SA, Gastman B, Haanen J, Hanley PJ, Hegde P, Hopewell EL, Levine BL, Locke FL, Maus MV, Nair NV, Nathenson M, Perales MA, Rivière I, Sikder D, Tendler C, Yee C, Luke J, O'Cearbhaill RE. Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles. Transplant Cell Therapy. (2026) Feb 26. doi: 10.1016/j.jtct.2026.02.054. https://pubmed.ncbi.nlm.nih.gov/41763313/
2024
- Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nature Communications. (2024)April:15:2863 https://www.nature.com/articles/s41467-024-46906-4